A carregar...
Combination of clinically utilized kappa opioid receptor agonist nalfurafine with low-dose naltrexone reduces excessive alcohol drinking in male and female mice
BACKGROUND: Nalfurafine is the first clinically approved kappa-opioid receptor (KOP-r) agonist as an anti-pruritus drug with few side effects in humans (e.g., sedation, depression and dysphoria). No study, however, has been done using nalfurafine on alcohol drinking in rodents or humans. METHODS: We...
Na minha lista:
| Publicado no: | Alcohol Clin Exp Res |
|---|---|
| Main Authors: | , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
2019
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6551307/ https://ncbi.nlm.nih.gov/pubmed/30908671 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/acer.14033 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|